Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2008

Conditions
Waldenstrom's MacroglobulinemiaLymphoplasmacytic Lymphoma
Interventions
DRUG

Thalidomide

200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.

DRUG

Rituximab

Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Cape Cod Hospital

OTHER

lead

Steven P. Treon, MD, PhD

OTHER

NCT00142116 - Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter